QPT — Quest PharmaTech Share Price
- CA$4.23m
- CA$4.72m
- 55
- 93
- 18
- 55
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.19 | ||
Price to Tang. Book | 0.19 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -4.59% | ||
Return on Equity | 53.01% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Jan | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. It also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Directors
- Last Annual
- January 31st, 2024
- Last Interim
- April 30th, 2024
- Incorporated
- December 16th, 1996
- Public Since
- July 23rd, 1997
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 169,129,247
- Address
- 4342 97 Street, EDMONTON, T6E 5R9
- Web
- http://www.questpharmatech.com/
- Phone
- +1 7804481400
- Contact
- Ragupathy Madiyalakan
- Auditors
- Kingston Ross Pasnak LLP
Upcoming Events for QPT
Quest Pharmatech Inc Annual Shareholders Meeting
Q3 2025 Quest Pharmatech Inc Earnings Release
Similar to QPT
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
Kane Biotech
TSX Venture Exchange
KDA
TSX Venture Exchange
FAQ
As of Today at 22:49 UTC, shares in Quest PharmaTech are trading at CA$0.03. This share price information is delayed by 15 minutes.
Shares in Quest PharmaTech last closed at CA$0.03 and the price had moved by -64.29% over the past 365 days. In terms of relative price strength the Quest PharmaTech share price has underperformed the Toronto Stock Exchange 300 Composite Index by -68.53% over the past year.
There is no consensus recommendation for this security.
Find out moreQuest PharmaTech does not currently pay a dividend.
Quest PharmaTech does not currently pay a dividend.
Quest PharmaTech does not currently pay a dividend.
To buy shares in Quest PharmaTech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.03, shares in Quest PharmaTech had a market capitalisation of CA$4.23m.
Here are the trading details for Quest PharmaTech:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: QPT
Based on an overall assessment of its quality, value and momentum Quest PharmaTech is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Quest PharmaTech. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -4.44%.
As of the last closing price of CA$0.03, shares in Quest PharmaTech were trading -54.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Quest PharmaTech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Quest PharmaTech's management team is headed by:
- Ragupathy Madiyalakan - CEO
- Pierre Vermette - CFO
- Shawn Shuguang Lu - IND
- W. John Meekison - IND